Q4 Earnings Forecast for ENVB Issued By HC Wainwright

Enveric Biosciences, Inc. (NASDAQ:ENVB) – HC Wainwright issued their Q4 2024 earnings per share (EPS) estimates for shares of Enveric Biosciences in a note issued to investors on Thursday, March 6th. HC Wainwright analyst V. Bernardino expects that the company will post earnings per share of ($0.23) for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Enveric Biosciences’ current full-year earnings is ($31.18) per share. HC Wainwright also issued estimates for Enveric Biosciences’ FY2025 earnings at ($0.86) EPS.

Enveric Biosciences Stock Performance

NASDAQ:ENVB opened at $1.82 on Monday. The stock has a market capitalization of $1.23 million, a PE ratio of -0.05 and a beta of 0.47. Enveric Biosciences has a fifty-two week low of $1.13 and a fifty-two week high of $28.05. The company has a fifty day moving average of $3.51 and a two-hundred day moving average of $5.44.

Institutional Trading of Enveric Biosciences

A hedge fund recently raised its stake in Enveric Biosciences stock. AdvisorShares Investments LLC raised its position in Enveric Biosciences, Inc. (NASDAQ:ENVB) by 63.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 599,854 shares of the company’s stock after buying an additional 232,807 shares during the period. AdvisorShares Investments LLC owned about 88.21% of Enveric Biosciences worth $215,000 at the end of the most recent reporting period. 13.82% of the stock is currently owned by institutional investors.

Enveric Biosciences Company Profile

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.